Analysts expect that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will post ($0.55) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.52). The company is scheduled to announce its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Tcr2 Therapeutics will report full year earnings of ($5.27) per share for the current year, with EPS estimates ranging from ($6.50) to ($4.59). For the next year, analysts anticipate that the company will post earnings of ($2.56) per share, with EPS estimates ranging from ($2.99) to ($1.74). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Tcr2 Therapeutics.
Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.11.
In other Tcr2 Therapeutics news, major shareholder Morana Jovan-Embiricos sold 64,104 shares of Tcr2 Therapeutics stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $17.11, for a total transaction of $1,096,819.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 39.07% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the business. EcoR1 Capital LLC purchased a new position in Tcr2 Therapeutics during the second quarter worth about $231,000. Laurion Capital Management LP purchased a new position in Tcr2 Therapeutics during the 1st quarter valued at about $417,000. Charles Schwab Investment Management Inc. purchased a new position in Tcr2 Therapeutics during the 2nd quarter valued at about $349,000. Parametric Portfolio Associates LLC grew its stake in Tcr2 Therapeutics by 23.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock valued at $501,000 after acquiring an additional 6,672 shares in the last quarter. Finally, Vanguard Group Inc. purchased a new position in Tcr2 Therapeutics during the 2nd quarter valued at about $1,070,000. 33.21% of the stock is currently owned by institutional investors.
Shares of NASDAQ:TCRR traded up $0.79 during midday trading on Friday, hitting $17.79. The company’s stock had a trading volume of 622 shares, compared to its average volume of 109,480. The business’s 50 day simple moving average is $16.98 and its 200 day simple moving average is $16.05. The company has a market cap of $405.99 million and a P/E ratio of -0.17. Tcr2 Therapeutics has a 12-month low of $10.04 and a 12-month high of $25.47.
About Tcr2 Therapeutics
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Recommended Story: Why is the LIBOR significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.